SCHEMBL21114396

SCHEMBL21114396

O=C(Cc1cccc(O)c1)OC(=O)Cc1cccc(O)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTBP2 P56545 1/20 0.54
ENPP2 Q13822 1/20 0.50
DRD2 P14416 1/20 0.47
DRD1 P21728 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MAPK1 P28482 2/20 0.46
CYP3A4 P08684 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HSP90AB1 P08238 1/20 0.46
CYP1A2 P05177 1/20 0.46
PKM P14618 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
LMNA P02545 2/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 1/20 0.44
BLM P54132 1/20 0.44
PMP22 Q01453 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL979023 0.85 HSP90AB1 (0.67) CTBP2ENPP2ALDH1A1MAPK1CYP3A4
SCHEMBL30435086 0.85 HSP90AB1 (0.67) CTBP2ENPP2ALDH1A1MAPK1CYP3A4
SCHEMBL56760 0.82 ALDH1A1 (0.73) CTBP2ENPP2ALDH1A1MAPK1L3MBTL1
SCHEMBL905142 0.82 CTBP2 (0.49) CTBP2ENPP2ALDH1A1MAPK1L3MBTL1
SCHEMBL22981807 0.81 CTBP2 (0.59) CTBP2ENPP2DRD2DRD1TAAR1
SCHEMBL30427127 0.81 CTBP2 (0.59) CTBP2ENPP2DRD2DRD1TAAR1
SCHEMBL21114392 0.81 DRD2 (0.53) ENPP2DRD2DRD1TAAR1TYR
SCHEMBL16273908 0.80 TSHR (0.67) CTBP2ENPP2DRD2DRD1TAAR1
SCHEMBL10918989 0.80 CTBP2 (0.47) CTBP2ENPP2DRD2DRD1TAAR1
3-Hydroxyphenylacetate SCHEMBL21114397 0.79 CTBP2 (0.62) CTBP2ENPP2DRD2DRD1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190214145-A1 Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen KUREK ITZHAK (US) 2019-07-11 US disclosed